Buccal Cavity Devices Market Size & Share, by Product Type (Drug Delivery Systems, Diagnostic Devices, Surgical Devices); Application; End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Buccal Cavity Devices Market Regional Analysis:

North America Market Analysis

North America is poised to dominate the global buccal cavity devices market while holding a share of 38.4% by the end of 2037. The increasing prevalence of chronic pain and opioid addiction is empowering the region's predominant captivity over this merchandise. Testifying the same, in 2024, the population of buccal films-eligible residents with chronic pain in North America crossed 25.4 million, as per the CDC. This represents a substantial growth in demand for fast-acting, non-invasive drug delivery systems, including buccal components. Besides, the presence of strong capital influx from both insurers and the Federal government in developed countries, such as the U.S. and Canada, is solidifying the region's leadership in this field.

The U.S. is augmenting a predominant control over the regional revenue generation from the buccal cavity devices market. The increased spending on non-invasive treatment options for pain management, oral diseases, and neurological disorders is a major asset for the country's lead in this sector. As evidence, the CMS recorded a 15.2% rise in Medicaid expenditure in this category over the tenure from 2020 to 2024, which provided financial backup for an additional 1.3 million eligible patients. Furthermore, continuous clinical discoveries and achievements in this sector within the nation's territory reflect a progressive trading atmosphere. In support of this cohort of innovation, in 2024 alone, the FDA cleared more than 11 associated IoT-enabled devices.

Canada is also showcasing robust growth in the buccal cavity devices market, remarking on its significance in the regional landscape. The continuous funding from governing bodies is the major propeller of this escalation. For instance, in 2023, healthcare allocation by the government of Ontario rose by 18.4%, totaling USD 3.3 billion, from 2021. In addition, the nationwide acceptance of affordable generics is opening new business opportunities for global leaders in this sector. In this regard, in 2024, Health Canada provided marketing clearance for 5 new biosimilar buccal film generics to escalate public access to advanced care. Moreover, the emergence of telemedicine in this country is also contributing to the field's expansion.

APAC Market Statistics

Asia Pacific is anticipated to register the highest CAGR in the global buccal cavity devices market between 2025 and 2037. The rapidly aging population, increasing prevalence of oral cancer, and wide adoption of sedentary lifestyles across the region are accumulatively amplifying the volume of the patient pool in this sector. In response, the governing authorities in high-risk countries are commencing awareness campaigns and subsidiary initiatives to combat the widespread. For instance, in 2024, the nationwide cancer screening programs in South Korea and Malaysia raised growth in the diagnostic buccal devices segment. Furthermore, technologically advanced countries are establishing a progressive environment of business in this landscape by integrating IoT features.

China is one of the largest raw material suppliers in the global buccal cavity devices market, which fosters the potential of regional leadership. For instance, in 2023, 40.3% of the net buccal drug delivery components imported by the U.S., worth USD 1.3 billion, originated from China. Furthermore, its exceptional capacity in localized API production satisfies 70.4% of domestic demand and reduces costs by 25.2%. In addition, the country also has a large patient pool, where more than 1.5 million afflicted residents were treated by therapeutics from this sector in 2024, as per the National Medical Products Administration (NMPA). Moreover, the nation consists of a favorable field for conducting a profitable business in this category.

India is emerging as a hub of innovation and a large consumer base for the buccal cavity devices market with robust support from governing authorities and increased oral disease prevalence. In this regard, a report from the NITI Aayog revealed that the annual government healthcare funding in India rose significantly from 2015 to 2024, reaching USD 1.9 billion. Additionally, the efforts from domestic leaders to bring affordability to patients in need are magnifying the rate of adoption in this landscape. To serve the same purpose, in 2023, Sun Pharma expanded treatment access to 2.5 million patients with the introduction of affordable $15.1/month generic buccal medications.